1988

CytRx

CytRx -Products to increase blood flow and dissolve clots for heart attacks and other blood vessel issues. Technology licensed from Emory University. Gorlin invested $200,000, raised additional funds and then took it public. The first IPO was $6 million. During Gorlin’s leadership, the company reached a market cap of over $200 million. NASDAQ: CYTR